Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies. | CPT Pharmacometrics Syst Pharmacol;3: e96, 2014 Jan 29. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies.

Li, L; Gardner, I; Rose, R; Jamei, M.

Affiliation

Li L; Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
Gardner I; Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
Rose R; Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
Jamei M; Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.

CPT Pharmacometrics Syst Pharmacol ; 3: e96, 2014 Jan 29.

Article in En | MEDLINE | ID: mdl-24477089

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2014 Document type: Article Affiliation country: Reino Unido Country of publication: Estados Unidos

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2014 Document type: Article Affiliation country: Reino Unido Country of publication: Estados Unidos